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Abstract
Background: Transcriptional profiling of prostate cancer (PC) has unveiled new markers of neoplasia and allowed insights into
mechanisms underlying this disease. Genomewide analyses have also identified new chromosomal abnormalities associated with
PC. The combination of both classes of data for the same sample cohort might provide better criteria for identifying relevant
factors involved in neoplasia. Here we describe transcriptional signatures identifying distinct normal and tumoral prostate tissue
compartments, and the inference and demonstration of a new, highly recurrent copy number gain on chromosome 17q25.3.
Methods: We have applied transcriptional profiling to tumoral and non-tumoral prostate samples with relatively homogeneous
epithelial representations as well as pure stromal tissue from peripheral prostate and cultured cell lines, followed by quantitative
RT-PCR validations and immunohistochemical analysis. In addition, we have performed in silico colocalization analysis of co-
regulated genes and validation by fluorescent in situ hybridization (FISH).
Results: The transcriptomic analysis has allowed us to identify signatures corresponding to non-tumoral luminal and tumoral
epithelium, basal epithelial cells, and prostate stromal tissue. In addition, in silico analysis of co-regulated expression of physically
linked genes has allowed us to predict the occurrence of a copy number gain at chromosomal region 17q25.3. This
computational inference was validated by fluorescent in situ hybridization, which showed gains in this region in over 65% of
primary and metastatic tumoral samples.
Conclusion: Our approach permits to directly link gene copy number variations with transcript co-regulation in association
with neoplastic states. Therefore, transcriptomic studies of carefully selected samples can unveil new diagnostic markers and
transcriptional signatures highly specific of PC, and lead to the discovery of novel genomic abnormalities that may provide
additional insights into the causes and mechanisms of prostate cancer.
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In a search for new molecular markers capable of confer-
ring more specificity and sensitivity to prostate cancer
(PC) diagnosis, many laboratories in the past few years
have applied transcriptomic profiling analyses, which
have unveiled new differentially expressed genes in non-
tumoral and tumoral prostate tissues. Expression microar-
rays have also been used to identify profiles characteristic
of metastasic disease [1], prostate intraepithelial neopla-
sia (PIN) [2], and subgroups of tumors with distinct out-
comes [3], including a 5-gene model predictive of
recurrence [4]. Several of these studies compared tumor
tissue with benign hyperplastic tissue, or with non-
tumoral prostate tissues that were not precisely character-
ized in terms of location or epithelial representation.
Therefore, the outcomes of these analyses, although iden-
tifying genes whose expression patterns were most
strongly altered in PC, were possibly biased because the
comparisons included tissues of diverse histological or
embryological origins, or with undefined epithelial and
stromal contents. The high degree of tissue heterogeneity
of the prostate represents a challenge for molecular stud-
ies of PC, and must be taken into account when perform-
ing high-throughput analyses. The representation of each
cell type within a given sample determines the overall
expression profile, which makes it difficult to compare
prostate samples which have very different epithelial and
stromal contents. One study addressed this issue by apply-
ing in silico corrections to compensate for variable epithe-
lial representations in different samples [5], whereas other
studies resorted to laser microdissection and in vitro linear
amplification [6].
Great efforts have also been dedicated to elucidate the
molecular bases of prostate carcinoma, which are begin-
ning to provide important mechanistic insights into some
of the key events in PC initiation and progression. For
example, the inactivation of the PTEN and p53 tumor sup-
pressor genes have been shown to play major roles in the
initiation of PC [7]. Also, fusions of TMPRSS2 (transmem-
brane protease, serine 2) with different members of the
ETS transcription factors family are likely relevant initiat-
ing factors in this neoplasia [8]. Moreover, genomewide
analyses of single nucleotide polymorphisms have
allowed the identification of polymorphisms and copy
number variations associated either with predisposition
to prostate cancer in familial clusters [9,10], or with the
occurrence and aggressiveness of prostate cancer [11].
In this study, we have performed a transcriptomic study of
carefully selected samples with the aim of finding expres-
sion profiles characteristic of the different cell type com-
partments of the prostate, to better understand the
molecular events responsible for this malignancy. Our
analysis has allowed the identification of transcriptional
profiles and new markers characteristic of different pros-
tate compartments, as well as a new highly recurrent gain
on chromosome 17q25.3 associated with prostate cancer.
Methods
Tissue samples and cell lines
Tissues were procured from untreated patients undergo-
ing radical prostatectomy for clinically localized prostate
adenocarcinoma at the Hospital Clínic of Barcelona. Sam-
ples were obtained after informed consent by the patients
and approval by the Institutional Ethics Committee. Tis-
sue fragments from tumoral and non-tumoral areas were
embedded in OCT, snap-frozen, and stored at -80°C at
the tumor bank of this institution (Table 1). Non-tumoral
samples were completely devoid of cells or glands with
neoplastic appearance upon histologic examination of
serial sections corresponding to the processed tissues, and
are hereafter called normal samples. The rest of the speci-
men was routinely formalin-fixed and paraffin-embed-
ded. HeLa and RWPE1 cells (ATCC, Manassas, VA) were
grown in DMEM (PAA, Ontario, Canada) supplemented
with 10% FBS or keratinocyte serum-free medium (KSFM;
Gibco, Carlsbad, CA), respectively. Primary cultures (PC1
and PC2) were derived from prostatectomies in which the
adenocarcinoma was macroscopically detected. Fibrob-
last-depleted explants were grown for 4–5 weeks in KSFM
supplemented with 10-11 M 5-α-dihydrotestosterone.
Total RNA isolation
Microscopical examination of hematoxylin-eosin (H&E)
stained sections from frozen tissues was used to assess the
percentage of each histological compartment (stroma,
total epithelium, normal and neoplastic epithelium) prior
to RNA extraction. Normal samples contained an average
of 45% epithelium, stromal samples, obtained from non-
tumoral areas of the specimens, contained less than 1%
epithelium and tumoral samples contained an average of
70% epithelium, being 90% of it neoplastic glands. At
least twenty 20-μm cryosections were used for RNA isola-
tion, and the first and the last sections were H&E-stained
to monitor for tumoral and normal gland status. RNA
from tissues and cell lines was isolated using RNeasy kits
with a DNase I digestion step (Qiagen, Valencia, CA), and
analyzed on a 2100 Bioanalyzer instrument (Agilent Tech-
nologies, Palo Alto, CA) to assess quality and quantity.
Microarray hybridization and data analysis
The samples used for microarray analyses were grouped in
four biological groups: adenocarcinomas (n = 20), nor-
mal samples (7 normal samples from 7 prostate cancer
patients and a pool of normal prostate tissues, n = 8), and
normal-associated stromal samples (n = 3), all of them
from the peripheral zone of the prostate, and the cell lines
described above (n = 4). Biotinylated cRNA (10 μg) from
the 35 samples enumerated above was processed andPage 2 of 12
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Table 1: Clinico-pathological characteristics of prostate samples
WHOLE TISSUE MICRODISSECTED (μD)
CASEa GLEASON 
SCORE
STAGE TUMORAL 
SAMPLES
%EPb %Tc NORMAL 
SAMPLES
%EPb %Tc STROMAL 
SAMPLES
NORMAL 
SAMPLES
TUMORAL 
SAMPLES
1 6 (3+3) T2 T1d, e 70 40 N1d, e 40 0 - N1-μDe T1-μDe
2 9 (4+5) T3a T2d 90 100 N2d 50 0 - - -
3 5 (2+3) T3a T3d, e 80 85 N3d, e 40 0 - N3-μDe T3-μDe
4 7 (3+4) T2 T4d 60 80 N4d 40 0 - N4-μDe T4-μDe
5 7 (4+3) T2 T5d 65 90 N5d 45 0 - - -
6 9 (5+4) T2 T6d, e 80 100 N6d, e 40 0 - N6-μDe T6-μDe
7 7 (3+4) T3a T7d, e 80 100 N7d, e 55 0 - N7-μDe T7-μDe
8 7 (3+4) T2c T8d 80 100 - - - S1 - -
9 8 (3+5) T2 T9d 80 90 - - - - - -
10 7 (3+4) T3a T10d 80 100 - - - - - -
11 7 (3+4) T3a T11d 70 80 - - - - - -
12 7 (3+4) T3a T12d 50 90 - - - - - -
13 9 (4+5) T3a T13d 80 100 - - - - - -
14 7 (3+4) T3a T14d 65 90 - - - - N14-μDe T14-μDe
15 7 (3+4) T3a T15d 70 100 - - - - - -
16 5 (2+3) T2 T16d 80 90 - - - - N16-μDe T16-μDe
17 7 (3+4) T3a T17d 80 95 - - - - - -
18 8 (3+5) T2 T18d 65 95 - - - - - -
19 6 (3+3) T2 T19d 70 90 - - - - - -
20 7 (4+3) T3a T20d 60 80 - - - - - -
21 - - - - - - - - S2 - -
22 - - - - - - - - S3 - -
- - - - - POOL Nd 45 0 - - -
aSamples in the same case line were obtained from the same patient.
bPercentage of epithelial cells.
cPercentage of epithelial cells with morphological features of carcinoma.
dSamples used in microarray analysis.
eSamples used in Q-PCR analysis
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(Affymetrix, Santa Clara, CA). Arrays were scanned at 3
μm resolution in an Agilent HP G2500A GeneArray scan-
ner (Agilent Technologies). Data were RMA-normalized
[12], followed by quantile-quantile probe-level between-
array normalization [13]. Normalized expression data
were analyzed by FADA [14], which applies Q-mode Fac-
tor Analysis. Genes were considered differentially
expressed between the tumoral and normal groups when
their associated q-value was below 2.5 × 10-4. Q-values
were computed from t-test P-values using the Benjamini-
Hochberg step-down false-discovery rate (FDR) algorithm
[15]. Normalized expression data were standardized and
submitted to UPGMA hierarchical clustering [16]. Micro-
array data sets from this study are deposited in the Array
Express repository under accession number E-MEXP-
1331.
Laser Microdissection
Tissue samples from seven of the patients whose samples
had been used in microarray analysis were selected for
laser microdissection (Table 1). Eight-μm cryosections
were mounted onto plastic membrane slides (PALM,
Bernried, Germany), fixed in cold 70% ethanol, stained
with hematoxylin, dehydrated, air-dried and stored at -
80°C until use. Laser microdissection was performed
using the PALM MicroBeam System, with the Laser Micro-
dissection and Pressure Catapulting technology. Approxi-
mately 1.2 mm2 of both normal and tumoral epithelium
were collected separately from each sample and RNA iso-
lation was performed as above.
Real-Time RT-PCR (Q-PCR)
Microdissected tissues and 4 paired normal-tumoral sam-
ples included in the microarray analysis were used for Q-
PCR analyses. Custom-designed TaqMan Low Density
Arrays (TLDA; Applied Biosystems, Foster City, CA) con-
tained primers and probes for 45 genes, and the RPS18
gene as the calibrator. One ng of total RNA was used as
template for reverse transcription for each replicate of
non-microdissected (triplicates) and microdissected
(quadruplicates) samples. Q-PCR was performed on an
ABI PRISM 7900 HT instrument (Applied Biosystems),
and relative quantitation determined by the ΔΔCt
method.
Immunohistochemistry
Tissue microarrays (TMA), were built using a Manual Tis-
sue Arrayer 1 (Beecher Instruments, Sun Prairie, WI), and
contained a total of 52 paraffin-embedded tumors, 21
PIN and 40 normal samples, each in duplicated or tripli-
cated cores. Two μm thickness TMA sections were
mounted on xylaned glass slides (DAKO, Glostrup, Den-
mark) and used for immunohistochemistry. Mouse mon-
oclonal antibodies specific for myosin VI (MYO6, clone
MUD19; 1/100 dilution) and ephrin type-A receptor 2
precursor (EPHA2, clone D7; 1/50 dilution) were pur-
chased from Sigma (Madrid, Spain) and a rat monoclonal
antibody specific for multidrug resistance-associated pro-
tein 4 (ABCC4, clone M4I-10; 1/50 dilution) was pur-
chased from Abcam (Cambridge, MA).
Immunohistochemistry was performed with the Envision
system (DAKO) and developed with diaminobenzidine,
after antigen retrieval in a pressure cooker with citrate
buffer pH 6 (MYO6) and EDTA pH 9 (ABCC4) or no
retrieval (EPHA2). The staining was scored as a percentage
of positive cells and its intensity as null (0), weak (1),
moderate (2) or strong (3). Differences over 20% in the
percentage of positive cells and/or one or more than one
degree of intensity were considered as a significant change
in expression. Images were obtained in an Olympus BHT
microscope (Olympus, Germany) with an Olympus
Camedia C-3030 camera. Immunohistochemistry infor-
mation is MISFISHIE compliant [17].
In silico analysis of chromosomal localizations of 
coexpressed genes
To determine putative non-random colocalizations of
coexpressed genes, we determined the precise genomic
localizations of all the genes present on the array
(ENSEMBL-NCBI 36 assembly of the consensus human
genome sequence). We then determined the groups of
four or more consecutive FADA-selected genes that were
all either over- or underexpressed in tumoral samples and
simultaneously colocalized within a distance of 4 Mb, or
less. We modelled the random distribution of over- or
underexpressed genes as a Poisson distribution, taking as
lambda parameter the product of the number of genes
present in the array within the tested region multiplied by
the total number of over- or underexpressed genes and
divided by the number of genes in the array.
Fluorescent in situ hybridization (FISH)
Tumoral samples from the same 20 adenocarcinoma cases
used in the microarray analysis and 8 lymph node metas-
tases were used. From each paraffin-embedded sample, a
2-μm section was obtained for FISH analysis and a consec-
utive tissue section was H&E-stained in order to identify
the tumoral and normal regions to be analyzed. Sections
were deparaffinized, washed in 2 × SSC, dehydrated,
denatured and hybridized with a BAC probe correspond-
ing to the segment of interest on 17q25.3 (RP11-165M24)
and a chromosome 17 centromeric probe (CEP17, Vysis,
Des Plaines, IL). Slides were then washed in 0.4 × SSC and
in 2 × SSC, counterstained with DAPI II (Vysis) and
imaged using an Olympus BX60 fluorescence microscope
(Olympus) with the MetaSystems software (MetaSystems,
Germany). Signals corresponding to both the RP11-
165M24 and the chromosome 17 centromeric probes
were scored in 200 non-overlapping nuclei of the tumoralPage 4 of 12
(page number not for citation purposes)
BMC Cancer 2008, 8:315 http://www.biomedcentral.com/1471-2407/8/315zone and gains were defined in samples where ≥ 10% of
the analyzed nuclei presented a ratio between the RP11-
165M24 and the reference probe ≥ 1.5. In all cases, a non-
tumoral area was analyzed to assess its normal chromo-
somic status.
Results
Transcriptional profiles of tumoral and normal prostate 
compartments
The specific features of our transcriptional profiling
included a stringent selection of normal and tumoral
prostate tissue samples, based on epithelial representa-
tions, the use of pure stromal samples, and the inclusion
of four epithelial cell cultures. These cell lines were HeLa
cells as a non-prostate epithelial cell line, a normal pros-
tate epithelial cell line (RWPE1) and two prostate primary
cultures, the last three with features of basal epithelial
cells, as discussed below. The microarray data analysis by
FADA permits to identify those genes that most signifi-
cantly contribute to a given phenotype, and to group the
samples according to their degree of biological relatedness
[14]. FADA identified 318 genes as those most signifi-
cantly differentially expressed between normal and
tumoral tissues. These genes clustered samples into four
groups according to their origin (tumoral, normal and
stromal samples, and a group comprising all cultured
cells, Figures 1A and 1B), and clustered genes into five
functional groups (non-tumoral, basal, normal luminal
and stromal, tumoral and tumoral-proliferative, Figure
1B). Of these genes, 134 were overexpressed and 184
underexpressed in tumoral vs. normal prostate tissues
(Figure 1B, see Additional files 1 and 2). The genes over-
expressed by tumors could be further subdivided into two
groups according to their coexpression in the different
sample groups: a tumoral gene set (99 genes), most
expressed in tumoral samples, and a tumoral and prolifer-
ative gene set (35 genes) most expressed in both tumoral
samples and cultured cells. Similarly, the genes underex-
pressed in tumors could be subdivided into three sub-
groups of coexpressed genes: a non-tumoral set (51
genes), expressed at high levels in normal prostate, pure
stromal and cultured cell samples, and at significantly
lower levels in tumoral samples; a normal luminal epithe-
lium and stromal set (105 genes), highly expressed in nor-
mal and stromal samples, but expressed at low levels in
tumoral samples or in cultured cells; and a basal epithelial
Graphical representation of microarray data analysisFigure 1
Graphical representation of microarray data analysis. A) Unrooted dendrogram showing the clustering of samples into 
four different classes: normal samples (blue), tumoral samples (red), stromal samples (yellow) and cultured cell lines (green). B) 
Unsupervised hierarchical cluster representation using microarray data for the 318 FADA-selected genes. T, tumoral samples; 
N, normal samples; S, pure stromal samples; CL, cell lines.Page 5 of 12
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ples and in cultured prostate epithelial cells, but weakly
expressed in tumoral or stromal samples or in non-pros-
tate HeLa cells. The consideration of the latter gene set as
characteristic of prostatic basal epithelium relies on the
facts that many of its member genes are known markers of
basal cells of prostate glands and other stratified epithelia,
such as those for tumor protein p63 (TP73L), keratin 5
(KRT5), keratin 7 (KRT7) and keratin 14 (KRT14), or lam-
inin beta 3 (LAMB3) [18,19], and that they lack expres-
sion of markers of prostate malignancy such as alpha-
methylacyl-coenzyme A racemase (AMACR, [20]) and
hepsin (HPN, [21,22]).
Laser microdissection and Q-PCR validations
As a validation of the microarray expression data, 45 out
of the 318 tumoral-normal discriminant genes selected by
FADA were further validated by Q-PCR on tumoral-nor-
mal paired samples, including whole tissue samples as a
technical validation and microdissected tissues in order to
assess whether the over- or underexpression of these genes
was associated with the epithelial component of the sam-
ples. These genes were selected for Q-PCR validation
according to their ranking by FADA for discrimination
between tumor vs. normal prostate samples, and their
capacity to correctly cluster samples into the above four
categories obtained by microarray analysis (Figure 2A).
For the four non-microdissected paired samples, 1 of the
45 genes analyzed could not be evaluated due to failure of
the TaqMan probe to yield reproducible quantitation. Of
the 44 remaining genes, 31 (31/44, 70%) presented
tumoral vs. normal Q-PCR ratios that were similar to, or
in the same direction as (upregulated or downregulated)
those determined by microarray analysis for the same
samples (Figure 2B and 2C). For the 7 microdissected
pairs, 43 of the 45 genes could be evaluated, 28 of which
(28/43, 65%) yielded tumor vs. normal Q-PCR ratios that
roughly corresponded to those determined by microar-
rays for the same samples, 26 of these 28 genes being coin-
cident with the 31 genes validated in non-microdissected
samples (Figure 2C). These results reflect the usefulness of
selecting samples with special attention to their histologi-
cal characteristics, but also the necessity of validating
microarray data results by complementary approaches
such as Q-PCR.
Immunohistochemical validation of selected new 
candidate markers of PC
The expression of proteins corresponding to several of the
above defined functional gene clusters was additionally
validated by immunohistochemistry on tissue microar-
rays. A monoclonal antibody to myosin VI (MYO6)
stained luminal cells with a homogeneous cytoplasmic
pattern, with tumor cells showing frequent apical rein-
forcement (Figure 3A and 3D). This protein was overex-
pressed in a majority of prostate tumors (41 of 49 samples
in which both tumoral and normal glands were repre-
sented in the same cores, 83.6%), and also in a majority
of PIN lesions (17 of 21 samples, 80.6%). The multidrug
resistance-associated protein 4 (ABCC4) showed a pre-
dominant membrane staining pattern (Figure 3B and 3E),
and was overexpressed in 82.9% (39 of 47 samples) of
tumor cases and in 81.25% (13 of 16 samples) of PIN
lesions. Finally, the ephrin type-A receptor 2 precursor
(EPHA2), whose transcript was underexpressed in
tumoral samples, was undetectable in luminal cells from
normal and tumoral glands or stroma, while it was
strongly expressed in a subpopulation of basal cells in
normal glands (Figure 3C and 3F), consistent with the
inclusion of this gene in the basal cell compartment signa-
ture.
In silico prediction and experimental validation of a 
recurrent genomic gain in 17q25.3
The analysis of colocalization of genes in adjacent posi-
tions in the genome can provide insights into higher levels
of regulation that determine the selective coexpression of
genes in cancer or putative regions of chromosomic insta-
bility [23]. The criteria used in this analysis included a sig-
nificant association of coexpression for 4 or more FADA-
selected genes colocalized within 4 Mb or less in the
genome. Our analysis found one cluster of contiguous
overexpressed genes with a significant bias in distribution
(p = 6.85 × 10-4), located on chromosome 17q25.3 (Fig-
ure 4A), which included five FADA-selected genes: synap-
togyrin 2 (SYNGR2), solute carrier family 25 member 10
(SLC25A10), procollagen-proline, 2-oxoglutarate 4-diox-
ygenase (proline 4-hydroxylase), beta polypeptide
(P4HB), pyrroline-5-carboxylate reductase 1 (PYCR1) and
dihydrouridine synthase 1-like (DUS1L). The last four
genes colocalize within a segment of less than 0.4 Mb. We
re-analyzed the expression profiles of the genes in the
17q25.3 region present in the microarrays used in this
study, and found that many of the genes in this region
were in fact overexpressed in a significant proportion of
tumors compared to both normal and stromal tissues,
even if they had not been selected in our original FADA
analysis because of their lower discriminant power when
taken individually (Figure 4B).
The relatively coordinate overexpression of so many
genes, with a tight genomic colocalization to 17q25.3,
could be due to genomic amplifications or gains of this
region or, alternatively, to the co-regulation by factors act-
ing in trans, or by a locus control region effect. In order to
address this issue, we performed fluorescent in situ hybrid-
ization (FISH) on paraffin-embedded samples, corre-
sponding to the same 20 cases analyzed for their
transcriptional profiles. The results showed a gain inPage 6 of 12
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Quantitative RT-PCR validation of selected genesFigure 2
Quantitative RT-PCR validation of selected genes. A) Hierarchical clusters built using microarray data corresponding to 
the 45 genes selected for Q-PCR validation. T, N, S and CL are as described in Fig. 1. B) Hierarchical sample and gene cluster 
generated with Q-PCR data for genes showing concordance with microarray data (either upregulated or downregulated in 
both determinations) in 4 normal-tumoral non-microdissected matched samples and 7 normal-tumoral microdissected 
matched samples. C) Graphical representation of the Q-PCR tumoral/normal ratios for the 26 genes showing the best con-
cordance with microarray data (9 overexpressed and 17 underexpressed in tumoral vs. normal samples). Shown are the aver-
ages for each of the selected genes of the Q-PCR tumoral/normal ratios for microdissected epithelia (light gray bars) and for 
whole, non-microdissected tissues (dark gray bars).
BMC Cancer 2008, 8:315 http://www.biomedcentral.com/1471-2407/8/31517q25.3 (Figure 4C) in a majority of tumors (13 out of 20,
65%), which was never observed in matched normal
glands. The median gain observed was 3 copies of the
region, which correlated well with the overall levels of
overexpression of the genes in this chromosomal region,
with ratios generally not above 2-fold (tumoral vs. normal
tissue). Genetic and phenotypic heterogeneity within
tumors is a recurring theme in prostate cancer [24], a pos-
sible reflection either of multiclonality or of clonal drift,
and it was also observed in this analysis. This heterogene-
ity was found amongst samples from different cases carry-
ing the alteration, where the percentage of cells with a gain
in 17q25.3 varied from 14% to 80%, with a mean of
47.4% nuclei containing the abnormality. Furthermore,
the 17q25.3 gain showed a heterogeneous distribution in
any given sample, with tumoral zones of the same sample
with and without this alteration. Since we could only ana-
lyze some regions of the samples, this heterogeneity sug-
gests that the observed prevalence of this segmental copy
number gain is most likely an underestimation.
Prostate intraepithelial neoplasia (PIN) lesions could be
analyzed near the tumoral zone in four of the tumors that
presented this gain. Although the number of PIN nuclei
were usually not sufficient for statistic significance, all
cases showed a gain in 17q25.3 (Figure 4D), suggesting
that this alteration is an early event in prostate cancer.
Finally, the frequent finding of this gain in more than
60% (5 of 8) of metastatic samples (Figure 4E), with a
mean of 69.4% of nuclei containing the alteration (rang-
ing from 47.5% to 98.5%), indicates that this alteration is
conserved during all steps of tumor progression.
Discussion
Our microarray analysis of highly selected prostate sam-
ples, which included normal, tumoral and stromal sam-
ples with defined epithelial and stromal representations,
and basal epithelial cell lines, has allowed us to identify
sets of genes specific of the major cellular compartments
in normal and tumoral prostate tissue. Each gene set
includes known markers of these compartments, which
lends support to our classification, and therefore permits
us to infer that other genes in these sets will be relevant in
each of these cell types. Amongst the genes included as
overexpressed in our prostate tumoral set, there are several
well-established PC markers, such as AMACR [20] and
HPN [21,22], or previously associated with PC, like those
for ectonucleoside triphosphate diphosphohydrolase 5
Immunohistochemical analysis of selected markersFigure 3
Immunohistochemical analysis of selected markers. A, D): Overexpression of myosin VI (MYO6) in tumoral (t) and 
PIN glands, as compared to normal (n) glands (inset, higher magnification showing a luminal reinforcement). B, E): Overexpres-
sion of multidrug resistance-associated protein 4 (ABCC4) in tumoral and PIN glands (inset in B, higher magnification showing 
a membrane staining pattern). C) Ephrin type-A receptor 2 precursor (EPHA2) was not detected in tumoral glands, while it 
was expressed in a subpopulation of basal cells in normal glands (n). F) Higher magnification showing a cytoplasmic and mem-
brane staining pattern of EPHA2. Bars correspond to 100 μm.Page 8 of 12
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Identification of a highly recurrent chromosomal gain on 17q25.3 in prostate tumors by transcript co-regulation analysisFigure 4
Identification of a highly recurrent chromosomal gain on 17q25.3 in prostate tumors by transcript co-regula-
tion analysis. A) Ideogram of chromosome 17 detailing the genes located on 17q25.3 with a corregulated overexpression in 
prostate cancer, as determined by our microarray analysis (red: genes selected by FADA as overexpressed in tumor samples; 
black: genes not selected by FADA but present in the Human Genome Focus microarrays; grey: genes not present in Human 
Genome Focus microarrays). B) Heat map showing the relative expression levels of the genes on 17q25.3 shown in (A). The 
order of the genes is from centromeric (top) to telomeric (bottom). Fluorescent in situ hybridization of prostate tissue samples 
(C, D and E) hybridized with the centromeric CEP17 probe (green) and the 17q25.3-specific BAC clone RP11-165M24 (red). 
Selected representative regions of prostate carcinoma (C) and PIN (D) areas from the same sample, and a lymph node metas-
tasis (E), illustrating copy number gains in 17q25.3. The figures shown are also representative of samples with a 17q25.3 gain.
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(TACSTD1), single-minded homolog 2 (SIM2) or myosin
VI (MYO6) [25,26]. Likewise, the tumoral and prolifera-
tive gene set includes the gene for cyclin-dependent kinase
5 (CDK5), which has been shown to regulate cell prolifer-
ation in thyroid carcinoma [27]. Similarly, several of the
genes in the non-tumoral set have been described as selec-
tively suppressed in PC, like those for caveolin-1 (CAV1)
[28], caveolin-2 (CAV2), annexin A2 (ANXA2) [29], or
glutathione-S-transferase π1 (GSTP1) [30]; some genes
such as desmin (DES), fibroblast growth factor 2 (FGF2)
or transforming growth factor beta receptor III (TGFBR3)
have been described to be predominantly expressed by the
stromal compartment [5]; finally, several genes in the
basal set are also known markers of basal cells of prostate
glands and other stratified epithelia, such as those for
tumor protein p63 (TP73L), keratin 5 (KRT5), keratin 7
(KRT7), keratin 14 (KRT14), or laminin beta 3 (LAMB3)
[18,19]; the underexpression of these genes in tumoral
samples could reflect the loss of this cell layer in prostate
tumors. Similarly, our immunohistochemical analyses
show that the ephrin type-A receptor 2 precursor
(EPHA2), which is classified in this basal gene set, is
expressed in a restricted compartment of the basal cell
layer. It is also worth noting that all these basal markers
are expressed at high levels by our primary cultures, sug-
gesting that they have basal cell features.
Further computational analysis of our FADA-selected
genes, in which we applied profiling-based in silico predic-
tions of genomic imbalances, have led us to the prediction
of a recurrent copy number gain in 17q25.3, a prediction
that was subsequently demonstrated experimentally by
FISH. This was the most significant genomic imbalance
predicted by our analysis, and, given the strong functional
significance of the gene sets selected by FADA, we suggest
that the 17q25.3 segmental gain may play a relevant role
in prostate carcinogenesis. Although comparative
genomic hybridization studies have revealed gains in dis-
tal segments of 17q in some tumors, including prostate
cancer [31,32], they have not been associated with the
precise region in 17q25.3 described in our study. Our
analysis suggests that this recurrent gain may involve a
region as small as 0.4 Mb in size, which may fall below the
resolution of genomewide BAC array analysis [33].
Considering only the most significantly biased four-gene
cluster on 17q25.3, there are 21 genes in the region com-
prised between SLC25A10, the most centromeric gene of
the cluster, and DUS1L, the most telomeric one, of which
13 are represented in the microarrays used in this study
(Figure 4A). Of these genes, of immediate interest in can-
cer are ARHGDIA, that codes for an inhibitor of GDP dis-
sociation from the ras-like cytoskeleton regulator Rho
[34]; ANAPC11, coding for an essential subunit of the
anaphase-promoting complex [35]; SIRT7, coding for an
homologue of the NAD+-dependent histone deacetylase
SIRT1 that regulates RNA polymerase II [3]; MAFG, whose
product is a basic region leuzine-zipper transcription fac-
tor that heterodimerizes with NRF-2 to regulate the tran-
scriptional response to oxidative stress, and also with Fos
and JunB [36,37]; and ASPSCR1 (also known as ASPL), a
gene that is frequently translocated in alveolar soft part
sarcomas and papillary renal cell carcinomas to the chro-
mosome X gene TFE3, causing the increased expression of
this transcriptional regulator [38]. Also located in this
region, immediately telomeric to DUS1L, is the fatty acid
synthase gene (FASN), a well known marker of malig-
nancy and progression in PC [39].
The discovery of gene copy number variations acquires
added significance if it is simultaneously correlated with
transcriptional profiling, a combined approach that few
studies have followed [23,40,41]. Thus, we believe that
the relevance of our finding of a novel recurrent gain in
17q25.3 in prostate cancer resides mainly on the facts that
it is correlated with coordinate overexpression of genes
that are tightly associated with that region, and that it is
the most significant copy number abnormality predicted
by our approach and that it is a recurrent gain, observed
in 65% of primary prostate cancer cases. This frequency is
significantly higher than most of the recurrent gene copy
number variations reported in association with prostate
cancer [11,41-44]. Although gains in 17q25.3 have been
reported by other laboratories as part of high-throughput
screenings aimed at identifying genomic alterations in
association with prostate cancer [41,43], they were not
analyzed in detail. Therefore, our identification is the first
to directly correlate this tumor-associated abnormality
with co-regulation of transcripts encoded by specific genes
in this region, applying a reverse-genetics approach that
combines transcriptomic analyses, in silico predictions
and experimental verification by FISH. Finally, the fact
that this genetic aberration is detected in PIN and also in
metastasis samples is suggestive of its involvement in all
the stages of malignant transformation and progression in
PC.
Conclusion
Careful selection of samples with known epithelial and
non-epithelial composition, and the inclusion of pure
prostate stromal tissues, combined with the application of
an inclusive, non-supervised analysis method based on
Factor Analysis (FADA), has permitted the extraction of
biologically significant sets of genes characteristic of pros-
tate cancer and of the major prostate tissue compart-
ments. Further analysis of transcript levels from these
FADA-selected genes, treated as coexpression of closely
linked genes, has allowed the identification of a highly
recurrent chromosomal gain on chromosome 17q25.3,Page 10 of 12
(page number not for citation purposes)
BMC Cancer 2008, 8:315 http://www.biomedcentral.com/1471-2407/8/315encompassing 21 genes. This chromosomal aberration is
present in 65% of primary prostate cancers and metas-
tases, and also in PIN lesions, making it one of the most
frequent genetic abnormalities associated with all stages
of malignancy in prostate cancer.
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